Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients

120Citations
Citations of this article
110Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease primarily affecting motor neurons. We recently identified intermediate-length polyglutamine (polyQ) expansions (27-33 Qs) in ataxin 2 as a genetic risk factor for sporadic ALS in North American ALS patients. To extend these findings, we assessed the ataxin 2 polyQ repeat length in 1294 European ALS patients and 679 matched healthy controls. We observed a significant association between polyQ expansions and ALS (>30 Qs; P= 6.2 × 10-3). Thus, intermediate-length ataxin 2 polyQ repeat expansions are associated with increased risk for ALS also in the European cohort. The specific polyQ length cutoff, however, appears to vary between different populations, with longer repeat lengths showing a clear association. Our findings support the hypothesis that ataxin 2 plays an important role in predisposing to ALS and that polyQ expansions in ataxin 2 are a significant risk factor for the disease. © The Author 2011. Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Lee, T., Li, Y. R., Ingre, C., Weber, M., Grehl, T., Gredal, O., … Gitler, A. D. (2011). Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Human Molecular Genetics, 20(9), 1697–1700. https://doi.org/10.1093/hmg/ddr045

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free